| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Income tax provision | NaN | NaN | NaN | 0 |
| Derivative loss | NaN | NaN | NaN | 2,505 |
| Net loss | -7,616 | -4,291 | -10,426 | -12,285 |
| Depreciation and amortization | 46 | 40 | 41 | 82 |
| Amortization of right of use asset | 90 | 90 | 86 | 173 |
| Amortization of discount on debt issued | 0 | 1 | 4,524 | NaN |
| Derivative loss | 0 | 0 | -7,040 | NaN |
| Change in fair value of senior secured note and warrant liability | 2,998 | 1,017 | NaN | NaN |
| Financing charges from issuance of senior secured note | NaN | 2,294 | NaN | NaN |
| Amortization of discount on debt issued | NaN | NaN | NaN | 2,371 |
| Provision for excess and obsolete inventory | 180 | -220 | 179 | 464 |
| Stock-based compensation | 165 | 226 | 204 | 324 |
| Loss on settlement of debt | -6,098 | NaN | NaN | NaN |
| Accounts receivable | -27 | -259 | -408 | 787 |
| Inventory | 321 | 531 | -266 | -655 |
| Prepaid expenses and other assets | 132 | 145 | 235 | -130 |
| Accounts payable | 632 | -1,038 | -3,250 | 1,077 |
| Accrued expenses and other liabilities | 121 | 43 | -383 | 701 |
| Operating lease obligation | -92 | -88 | -92 | -192 |
| Net cash used in operating activities | -3,800 | -4,377 | -6,514 | -4,782 |
| Net cash used in investing activities | NaN | NaN | 0 | NaN |
| Purchase of plant, property and equipment | 26 | NaN | NaN | NaN |
| Net cash used in investing activities | -26 | NaN | 0 | 0 |
| Proceeds from loans from related parties | 700 | 1,001 | 1,156 | 1,752 |
| Repayments of loans from related parties | 866 | -24 | 8,124 | 90 |
| Proceeds from notes payable | NaN | 13,500 | NaN | NaN |
| Financing costs paid | NaN | 1,488 | NaN | NaN |
| Issuance of convertible notes | 0 | 0 | 0 | 2,000 |
| Payments of senior secured note | 7,379 | 0 | 25 | NaN |
| Stock option exercise | 42 | NaN | NaN | NaN |
| Proceeds from issuance of common stock | 0 | 0 | 13,724 | 1,485 |
| Proceeds from subscription of common stock | NaN | 0 | 2,235 | NaN |
| Repayment of finance lease obligations | 19 | 20 | 17 | 35 |
| Net cash provided by (used in) financing activities | -7,522 | 13,017 | 8,949 | 5,112 |
| Effect of exchange rate changes on cash and cash equivalents | 18 | -2 | -32 | -16 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | -11,330 | 8,638 | 2,403 | 314 |
| Cash, cash equivalents, and restricted cash at beginning of the period | 11,451 | 2,813 | 96 | NaN |
| Cash and cash equivalents at end of the period | 121 | 11,451 | 2,813 | NaN |
Picard Medical, Inc. (PMI)
Picard Medical, Inc. (PMI)